Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday

The company claims it can make 100 million doses of mRNA vaccine within 18 months.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is shooting 25% higher after The Sydney Morning Herald (SMH) reported the company is seeking to work with the federal government to produce mRNA vaccines in Australia.

At the time of writing, shares in the pharmaceutical company are trading for 46.5 cents each – up 25.68%.

Let's take a closer look at what's getting investors so excited.

IDT says it can manufacture mRNA vaccines in Australia

The COVID-19 pandemic has heralded the first wide-scale use of mRNA vaccines. The leading products in this space are the inoculations jointly produced by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), as well as the Moderna Inc (NASDAQ: MRNA) jab.

In an effort to secure domestic supply through the production of the vector for single-strand RNA of viruses, the federal government has been in talks with the companies in a bid to secure a licence for their COVID vaccines to be made in Australia. As well as IDT, CSL Limited (ASX: CSL) is interested in the production of mRNA vaccines on our shores.

IDT says what differentiates its offer from CSL's is it will use existing manufacturing capabilities located near Melbourne's Monash University to make the product. CSL is proposing 2 new facilities for the endeavour, according to the SMH.

The prospect of IDT being awarded a lucrative government contract may be exciting investors, judging by the IDT share price rise.

"This is an established site with an established equipment train in it, which we will expand, and I think that gives us a material time advantage," IDT Chief Executive David Sparling is quoted in the SMH as saying.

"We've formed an alliance with numerous research bodies around the country, including Monash University, and that builds an ecosystem for mRNA."

Dr Sparling further went on to tell the paper his company could produce "100 million doses within 18 months."

IDT says it wants to build an mRNA research facility near its production site if it secures the licence to make the product. Dr Sparling did not reveal any financial details to the SMH.

Motley Fool Australia reached out to IDT for comment. Dr Spalding responded that the reports in the SMH are accurate and that he had nothing further to add beyond what was already in the public domain.

IDT share price snapshot

Over the past 12 months, the IDT share price has increased 141%. The company's shares faced a similar boom when IDT revealed it was in discussions with the Victorian government over a proposed mRNA vaccine plant.

IDT Australia has a market capitalisation of around $104 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »